CSTONE PHARMA-B (02616): CEO and Executive Director Yang Jianxin Bo purchased an additional 560,000 shares of the company, totaling 10,359,000 shares purchased.

CSTONE PHARMA-B (02616) Announcement: The company's CEO, Chief Scientific Officer, and Executive Director, Dr. Yang Jianxin (Dr. Yang), informed that he purchased a total of 560,000 shares of the company with his own funds on the open market from April 2 to April 7, 2025 (share purchase), at prices ranging from HK$2.26 to HK$3.29 per share. Since assuming the role of CEO in August 2022, Dr. Yang has accumulated a total of 10.359 million shares at prices ranging from HK$0.82 to HK$4.60 per share. Following this share purchase, Dr. Yang now holds approximately 5.46% of the company's issued share capital as of the date of this announcement. Dr. Yang expressed his confidence in the company's future prospects and stated that his increased stake in the company reflects his belief that the company is capable of maintaining stable operations while achieving rapid growth in the complex and changing market environment. He also reiterated his unwavering support for the company's growth and development. Dr. Yang did not rule out the possibility of further increasing his stake in the company at the right time. The Board of Directors of the company believes that Dr. Yang's increase in his stake in the company reflects his long-term commitment to the company and his confidence in its future business prospects.